Thus, tumor downregulation of CD1d may be advantageous for evasion of iNKT-mediated immune surveillance in the early stages of tumor progression, when antigens presented by tumor cells such as TM40D may preferentially elicit type I over type II NKT antitumor immune responses. The gene discussed is CD1D; the disease is neoplasm.